Fundamental Data for BIIB

BIOGEN IDE(NSDQ:BIIB)

IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research, development and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. Their first commercial product, Rituxan, and our most advanced product candidate, ZEVALIN, are for use in the treatment of certain B-cellnon-Hodgkin''s lymphomas. They are also developing products for the treatment of various autoimmune diseases (such as psoriasis, rheumatoidarthritis and lupus).

# Employees: 4700

Address: 14 Cambridge Center,Cambridge,MA,USA

Phone: 617 679-2000

Fax: 617-679-2617

Website: www.idecpharm.com

Email: idecir@idecpharm.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

James C. Mullen (Pres.; C.E.O.; Dir.)

Bruce R. Ross (Chmn)

Michael F. Maclean (Sr. V.P.; C.A.O.; Princ. Acctg. Off.)

Paul J. Clancy (Exec. V.P.; C.F.O.)

Lawrence C. Best (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/5/2010

Mean EPS (Next Qtr): $1.06

Mean EPS (Year): $3.93

Mean Estimate(Long Term): $9.33

P/E Ratio(Based on EPS estimate): 11.930

Number of Estimates: 10

Shares Performance

Period	BIIB	Compare to S&P
YTD	-1.49 %	-18.48 %
4 Weeks	11.37 %	5.73 %
12 Weeks	-8.02 %	-14.35 %

Shares Information

Analyst Coverage: Y

Avg Volume: 3813666

Shares Outstanding: 288M

Market Cap: $13.55B

52 Week High: $53.64

52 Week Low: $39.02

P/E Ratio: 12.410

PEG Ratio: 1.280

Split: On 1/18/2001 BIIB split by factor of 3.000

Earnings Performance

EPS Growth in Last Quarter: 49.32 %

EPS Growth in Last Year: 14.74 %

Sales Growth in Last Quarter: 2.49 %

Sales Growth in Last Quarter: 2.52 %

Financials

Qtr Book Value: $2.05

Cash Flow/Share: $8.99

Change in Payout Ratio: 0.000

Price/Sales: 3.140